Moderna reported a massive miss on revenue in its Q3 earnings, taking in $5 billion versus the expected $6.21 billion despite sales of the COVID-19 vaccine. The pharmaceutical giant's stock dropped sharply on the news.
R.J. Hottovy, Head of Analytical Research at Placer.ai, unpacks the recent changes at Starbucks and if the brand refresh has helped the business. Watch!
